Alx oncology to report fourth quarter and full year 2024 financial results on march 6, 2025

South san francisco, calif., feb. 27, 2025 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on thursday, march 6th, 2025, before market open.
ALXO Ratings Summary
ALXO Quant Ranking